Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN89,1889,280,20
Msft4,21
Nokia5,235,2344,60
IBM-1,54
Daimler AG83,3483,36-0,26
PFE-1,35
28.10.2021 9:57:53
Indexy online
AD Index online
select
AD Index online
 

  • 27.10.2021
Accelerate Diagnostics Inc, Ordinary, NASDAQ Stock Exchange Capital Market (NASDAQ Cons)
Závěr k 27.10.2021 Změna (%) Změna (USD) Objem obchodů (ks)
5,77 -2,04 -0,12 249 369
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.10.2021
Popis společnosti
Obecné informace
Název společnostiAccelerate Diagnostics Inc
TickerAXDX
Kmenové akcie:Ordinary Shares
RICAXDX.O
ISIN-
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky30.06.2021
Počet zaměstnanců k 31.12.2020 224
Akcie v oběhu k 04.08.2021 61 498 695
MěnaUSD
Kontaktní informace
Ulice3950 S. Country Club Road #470
MěstoTUCSON
PSČ85714-2240
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 038 638 088
Fax13026555049

Business Summary: Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Financial Summary: BRIEF: For the six months ended 30 June 2021, AccelerateDiagnostics Inc revenues increased 19% to $5.3M. Net lossincreased 13% to $45.9M. Revenues reflect Products segmentincrease from $1.9M to $4.7M, Services segment increasefrom $188K to $616K, Domestic(United States) segmentincrease of 11% to $4.5M, Foreign segment increase from$377K to $785K. Higher net loss reflects Stock-basedCompensation in SGA increase of 85% to $11.2M (expense).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYScientific & Technical Instr.
MGSECTORTechnology
NAICS2007Analytical Laboratory Instrument Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS1997Analytical Laboratory Instrument Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICAnalytical Instruments
SICAnalytical Instruments
SICElectromedical Equipment



  • Poslední aktualizace: 28.10.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardJohn Patience7326.09.201226.09.2012
President, Chief Executive Officer, DirectorJohn Phillips5501.02.202006.08.2019
Chief Financial OfficerSteve Reichling4210.09.201210.09.2012
Chief Commercial Officer, AmericasRon Price57